Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 5,467 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Solid Tumor Malignancies, Cancer Clear all

Conditions: Advanced Solid Tumor
Interventions: STP1002; Drug
Lead sponsor: ST Pharm Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Denver, Colorado • Evanston, Illinois

Conditions: Neoplasms
Interventions: DOXIL/CAELYX reference product (Treatment A), DOXIL/CAELYX test product (Treatment B); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions: GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab; Drug
Lead sponsor: GI Innovation, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Solid Tumor
Interventions: Tumor-associated antigen-specific T cell (TAA-T); Biological
Lead sponsor: Children's National Research Institute; Other
Eligibility: 1 Year to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Solid Tumor Refractory to Standard Therapy
Interventions: SQ001 125mL/day, SQ001 250mL/day, SQ001 500mL/day, SQ001 625mL/day, Saline 0.9%; Drug
Lead sponsor: Livzon Pharmaceutical Group Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: capecitabine, imatinib mesylate; Drug
Lead sponsor: Herbert Hurwitz; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer, Esophagus Cancer, Lung Cancer, Nonsmall Cell, Squamous Cell Carcinoma of the Head and Neck
Interventions: Tisotumab Vedotin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Advanced Solid Tumor, Non-small Cell Lung Cancers
Interventions: Adagrasib, Olaparib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor
Interventions: CAdVEC; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2038
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumors, Pancreatic Cancer
Interventions: ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Birmingham, Alabama • Gainesville, Florida • Sarasota, Florida + 2 more

Conditions: Solid Tumor, Metastatic Bladder Cancer
Interventions: RX-3117; Drug
Lead sponsor: Processa Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 12
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 9 more

Conditions: NSCLC, Melanoma
Interventions: BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta); Biological · Drug
Lead sponsor: BioAtla, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • Atlanta, Georgia • Dyer, Indiana + 5 more

Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Interventions: tabelecleucel; Biological
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: Not listed
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 40
States / cities: Duarte, California • La Jolla, California • Loma Linda, California + 28 more

Conditions: Gastrointestinal Neoplasms
Interventions: Risvutatug Rezetecan; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Los Alamitos, California • Los Angeles, California • Santa Monica, California + 8 more

Conditions: Carcinoma, Renal Cell
Interventions: GW786034, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • Orange, California + 8 more

Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: avelumab, Bempegaldesleukin, talazoparib, enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Medical Oncology
Interventions: BAY1217389, Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, topotecan hydrochloride, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cancer
Interventions: MEDI-575; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Denver, Colorado • Indianapolis, Indiana • Las Vegas, Nevada + 2 more

Conditions: Neoplasms
Interventions: GSK3901961, GSK3845097, GSK4427296, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 9
States / cities: Jacksonville, Florida • Atlanta, Georgia • Westwood, Kansas + 5 more

Conditions: Neoplasms
Interventions: GSK1795091, GSK3174998, GSK3359609, Pembrolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Boston, Massachusetts • St Louis, Missouri • Dallas, Texas + 2 more

Conditions: Advanced Solid Tumors
Interventions: ACY-241; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Boston, Massachusetts + 1 more

Conditions: Solid Tumors
Interventions: CEP-37440; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania • San Antonio, Texas

Conditions: Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions: PF-08046876, Pembrolizumab, Cisplatin, Carboplatin; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 21
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 11 more

Search by objective public record fields.

First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors